Theravance Biopharma (NASDAQ:TBPH) Reaches New 52-Week High – Here’s Why

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) reached a new 52-week high during mid-day trading on Saturday . The stock traded as high as $10.90 and last traded at $10.47, with a volume of 508066 shares. The stock had previously closed at $9.67.

Theravance Biopharma Trading Up 8.3 %

The company has a market capitalization of $514.81 million, a price-to-earnings ratio of -10.37 and a beta of 0.21. The stock has a 50-day simple moving average of $9.45 and a 200-day simple moving average of $8.91.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of TBPH. BNP Paribas Financial Markets grew its position in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after buying an additional 143,781 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after purchasing an additional 135,426 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Theravance Biopharma during the 2nd quarter worth approximately $986,000. Algert Global LLC bought a new stake in shares of Theravance Biopharma in the 3rd quarter worth approximately $851,000. Finally, Bank of Montreal Can boosted its position in Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after purchasing an additional 93,702 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.